{
  "Gene": "R-synuclein (RS)",
  "variants": [
    {
      "cDNA Change": {
        "transcript": "N.D.",
        "ref": "N.D.",
        "alt": "N.D.",
        "position": "N.D."
      },
      "Protein Change": {
        "ref": "A",
        "alt": "P",
        "position": "30"
      },
      "Description in input context": "The A30P mutation decreases lipid affinity relative to wild-type RS and is associated with increased toxicity due to elevated SL1 binding mode."
    },
    {
      "cDNA Change": {
        "transcript": "N.D.",
        "ref": "N.D.",
        "alt": "N.D.",
        "position": "N.D."
      },
      "Protein Change": {
        "ref": "E",
        "alt": "K",
        "position": "46"
      },
      "Description in input context": "The E46K mutation increases lipid binding relative to wild-type RS and is associated with increased toxicity due to elevated SL1 binding mode."
    },
    {
      "cDNA Change": {
        "transcript": "N.D.",
        "ref": "N.D.",
        "alt": "N.D.",
        "position": "N.D."
      },
      "Protein Change": {
        "ref": "A",
        "alt": "T",
        "position": "53"
      },
      "Description in input context": "The A53T mutation has comparable lipid affinity to wild-type RS but is associated with increased toxicity due to elevated SL1 binding mode."
    }
  ],
  "Clinical Significance": "N.D.",
  "Functional Impact": "These mutations alter lipid binding properties and promote the formation of disease-associated oligomers and fibrils, contributing to Parkinson's disease.",
  "Additional Notes": "The mutations A30P, E46K, and A53T in R-synuclein are associated with familial forms of Parkinson's disease."
}